À¯·´ÀÇ ¹é½Å º¸Á¶Á¦ ½ÃÀå ¿¹Ãø(-2030³â) : Áö¿ªº° ºÐ¼® - Ç׿øº¸°­Á¦ Ŭ·¡½ºº°, À¯Çüº°
Europe Vaccine Adjuvants Market Forecast to 2030 - Regional Analysis - by Adjuvant Class (Mineral Salt Adjuvant, Emulsion Adjuvant, Liposome Adjuvant, and Others) and Type (Human Vaccine Adjuvant and Veterinary Vaccine Adjuvant)
»óǰÄÚµå : 1666310
¸®¼­Ä¡»ç : The Insight Partners
¹ßÇàÀÏ : 2025³â 01¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 93 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,450 £Ü 4,895,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù.
US $ 4,450 £Ü 6,314,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,450 £Ü 7,734,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

À¯·´ÀÇ ¹é½Å º¸Á¶Á¦ ½ÃÀåÀº 2022³â¿¡ 7¾ï 4,050¸¸ ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. 2030³â¿¡´Â 20¾ï 5,105¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2022-2030³â°£ 13.6%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» º¸ÀÏ Àü¸ÁÀÔ´Ï´Ù.

µ¿¹°¿ë ¹é½Å º¸Á¶Á¦ ½ÂÀÎÀ¸·Î À¯·´ÀÇ ¹é½Å º¸Á¶Á¦ ½ÃÀå °ßÀÎÇÒ °Í

ÀϹÝÀûÀÎ Áúº´¿¡ ´ëÇÑ ¹é½Å Á¢Á¾Àº Ãà»ê¾÷¿¡¼­ Àü¿°º´À¸·Î ÀÎÇÑ °æÁ¦Àû ¼Õ½Ç ¹× ±âŸ ¼Õ½ÇÀ» ¹æÁöÇϱâ À§ÇØ Àü ¼¼°èÀûÀ¸·Î °¡Àå ¼º°øÀûÀÎ ¹æ¹ýÀÔ´Ï´Ù. µ¿¹°¿ë ¹é½Å º¸Á¶Á¦¿¡ ´ëÇÑ ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎÀº Áõ°¡ Ãß¼¼¿¡ ÀÖÀ¸¸ç, Á¦Á¶¾÷üµéÀº ´õ ³ôÀº È¿´É°ú ¾ÈÁ¤¼ºÀ» °¡Áø ¹é½Å °³¹ß¿¡ ÁýÁßÇϰí ÀÖ½À´Ï´Ù. ¸óŸ³ªÀ̵å´Â µ¿¹°¿ë ¹é½Å º¸Á¶Á¦ Áß Çϳª·Î ¾Ë·ÁÁ® ÀÖ½À´Ï´Ù. ¸óŸ³ªÀ̵åÀÇ º¸Á¶Á¦ Á¦Ç°±ºÀº ¿¡¸ÖÁ¯, ¸¶ÀÌÅ©·Î ¿¡¸ÖÁ¯, Æú¸®¸ÓÀÇ ¼¼ °¡Áö ÇÙ½É ±â¼úÀ» ±â¹ÝÀ¸·Î ÇÕ´Ï´Ù. µû¶ó¼­ µ¿¹°¿ë ¹é½Å º¸Á¶Á¦ Çã°¡°¡ ±ÞÁõÇϸ鼭 Àüü ¹é½Å º¸Á¶Á¦ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù.

À¯·´ÀÇ ¹é½Å º¸Á¶Á¦ ½ÃÀå °³¿ä

À¯·´ÀÇ ¹é½Å º¸Á¶Á¦ ½ÃÀåÀº µ¶ÀÏ, ¿µ±¹, ÇÁ¶û½º, ÀÌÅ»¸®¾Æ, ½ºÆäÀÎ, ±âŸ À¯·´À¸·Î ±¸ºÐµË´Ï´Ù. µ¶ÀÏ¿¡´Â ¿©·¯ ÁÖ¿ä ¹é½Å Á¦Á¶¾÷ü°¡ ÁøÃâÇØ ÀÖÀ¸¸ç, 2022³â 12¿ù EvonikÀº ¹é½ÅÀÇ È¿´ÉÀ» Çâ»ó½Ã۱â À§ÇØ PhytoSqueneÀ̶ó´Â ½Ä¹° À¯·¡ ½ºÄí¾Ë·»À» Ãâ½ÃÇß½À´Ï´Ù. PhytoSqueneÀº ºñ°æ±¸¿ë ÀǾàǰÀÇ º¸Á¶Á¦·Î ½ÃÀå¿¡ Ãâ½ÃµÈ ÃÖÃÊÀÇ ¾Æ¸¶¶õ½º ¿ÀÀÏ¿¡¼­ ÃßÃâÇÑ ½ºÄí¾Ë·»À¸·Î, ¹é½Å ¹× ±âŸ ÀǾàǰ ÀÀ¿ë ºÐ¾ß¿¡ ÀûÇÕÇÑ ºñµ¿¹°¼º À¯µµÃ¼ÀÔ´Ï´Ù. 2021³â¿¡ EvonikÀº Á¦¾à µî±ÞÀÇ ½Ä¹°¼º ÄÝ·¹½ºÅ×·ÑÀÎ PhytocolÀ» Ãâ½ÃÇß½À´Ï´Ù.

À¯·´ÀÇ ¹é½Å º¸Á¶Á¦ ½ÃÀå ¸ÅÃâ ¹× 2030³â±îÁöÀÇ ¿¹Ãø(±Ý¾×)

À¯·´ÀÇ ¹é½Å º¸Á¶Á¦ ½ÃÀå ¼¼ºÐÈ­

À¯·´ÀÇ ¹é½Å º¸Á¶Á¦ ½ÃÀåÀº º¸Á¶Á¦ À¯Çü, À¯Çü, ±¹°¡º°·Î ºÐ·ùµË´Ï´Ù.

º¸Á¶Á¦ À¯Çü¿¡ µû¶ó À¯·´ÀÇ ¹é½Å º¸Á¶Á¦ ½ÃÀåÀº ¹Ì³×¶ö ¼Ò±Ý º¸Á¶Á¦, ¿¡¸ÖÁ¯ º¸Á¶Á¦, ¸®Æ÷Á» º¸Á¶Á¦, ±âŸ·Î ºÐ·ùµÇ¸ç, 2022³â À¯·´ÀÇ ¹é½Å º¸Á¶Á¦ ½ÃÀå Á¡À¯À²Àº ¹Ì³×¶ö ¼Ò±Ý º¸Á¶Á¦ ºÎ¹®ÀÌ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

À¯Çüº°·Î À¯·´ÀÇ ¹é½Å º¸Á¶Á¦ ½ÃÀåÀº ÀÎü¿ë ¹é½Å º¸Á¶Á¦¿Í µ¿¹°¿ë ¹é½Å º¸Á¶Á¦·Î ³ª´µ¸ç, 2022³â À¯·´ÀÇ ¹é½Å º¸Á¶Á¦ ½ÃÀå¿¡¼­ ÀÎü¿ë ¹é½Å º¸Á¶Á¦ ºÎ¹®ÀÌ Å« ºñÁßÀ» Â÷ÁöÇß½À´Ï´Ù.

±¹°¡º°·Î À¯·´ÀÇ ¹é½Å º¸Á¶Á¦ ½ÃÀåÀº µ¶ÀÏ, ¿µ±¹, ÇÁ¶û½º, ÀÌÅ»¸®¾Æ, ½ºÆäÀÎ, ±âŸ À¯·´À¸·Î ±¸ºÐµÇ¸ç, 2022³â À¯·´ÀÇ ¹é½Å º¸Á¶Á¦ ½ÃÀå Á¡À¯À²Àº µ¶ÀÏÀÌ µ¶Â÷ÁöÇß½À´Ï´Ù.

Croda International Plc, CSL Ltd, Dynavax Technologies Corp, GSK Plc, InvivoGen SAS, Novavax Inc, Phibro Animal Health Corp, Seppic SA, SPI Pharma Inc´Â À¯·´ÀÇ ¹é½Å º¸Á¶Á¦ ½ÃÀå¿¡¼­ »ç¾÷À» Àü°³ÇÏ´Â ÁÖ¿ä ±â¾÷ÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå Á¶»ç ¹æ¹ý

Á¦4Àå À¯·´ÀÇ ¹é½Å º¸Á¶Á¦ ½ÃÀå : ÁÖ¿ä ½ÃÀå ¿ªÇÐ

Á¦5Àå ¹é½Å º¸Á¶Á¦ ½ÃÀå : À¯·´ ½ÃÀå ºÐ¼®

Á¦6Àå À¯·´ÀÇ ¹é½Å º¸Á¶Á¦ ½ÃÀå ºÐ¼® : Ç׿øº¸°­Á¦ Ŭ·¡½ºº°

Á¦7Àå À¯·´ÀÇ ¹é½Å º¸Á¶Á¦ ½ÃÀå ºÐ¼® : À¯Çüº°

Á¦8Àå À¯·´ÀÇ ¹é½Å º¸Á¶Á¦ ½ÃÀå : ±¹°¡º° ºÐ¼®

Á¦9Àå ¾÷°è »óȲ

Á¦10Àå ±â¾÷ °³¿ä

Á¦11Àå ºÎ·Ï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The Europe vaccine adjuvants market was valued at US$ 740.50 million in 2022 and is expected to reach US$ 2,051.05 million by 2030; it is estimated to register a CAGR of 13.6% from 2022 to 2030 .

Approvals of Veterinary Vaccine Adjuvants Drive Europe Vaccine Adjuvants Market

Vaccinating animals against common diseases remains the most successful method worldwide to prevent financial and other losses from infectious diseases in animal farming. Regulatory approvals for veterinary vaccine adjuvants are increasing, with manufacturers' growing focus on developing vaccines with greater efficacy and stability. Montanide is one of the known veterinary vaccine adjuvants. The Montanide adjuvant range is based on three core technologies-emulsions, micro-emulsions, and polymers. Therefore, an upsurge in adjuvant approvals for veterinary vaccines accelerates the overall market growth of vaccine adjuvants.

Europe Vaccine Adjuvants Market Overview

The Europe vaccine adjuvant market has been segmented into Germany, UK, France, Italy, Spain, and the Rest of Europe. A few top vaccine manufacturers have a presence in Germany. In December 2022, Evonik launched a plant-based squalene named PhytoSquene to improve vaccine efficacy. It is a non-animal derivative suitable for vaccines and other pharmaceutical applications. PhytoSquene is the first known amaranth oil-derived squalene introduced in the market for adjuvants in drugs indicated for parenteral usage. This latest innovation of Evonik is meant to provide the market with sustainable, non-animal derivative solutions. In 2021, Evonik launched the pharma-grade and plant-derived cholesterol "PhytoChol".

Europe Vaccine Adjuvants Market Revenue and Forecast to 2030 (US$ Million)

Europe Vaccine Adjuvants Market Segmentation

The Europe vaccine adjuvants market is categorized into adjuvant class, type, and country.

Based on adjuvant class, the Europe vaccine adjuvants market is segmented into mineral salt adjuvant, emulsion adjuvant, liposome adjuvant, and others. The mineral salt adjuvant segment held the largest share of the Europe vaccine adjuvants market share in 2022.

By type, the Europe vaccine adjuvants market is bifurcated into human vaccine adjuvant and veterinary vaccine adjuvant. The human vaccine adjuvant segment held a larger share of Europe vaccine adjuvants market in 2022.

By country, the Europe vaccine adjuvants market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Germany dominated the Europe vaccine adjuvants market share in 2022.

Croda International Plc; CSL Ltd; Dynavax Technologies Corp; GSK Plc; InvivoGen SAS; Novavax Inc.; Phibro Animal Health Corp; Seppic SA; and SPI Pharma Inc are some of the leading companies operating in the Europe vaccine adjuvants market.

Table Of Contents

1. Introduction

2. Executive Summary

3. Research Methodology

4. Europe Vaccine Adjuvants Market - Key Market Dynamics

5. Vaccine Adjuvants Market -Europe Market Analysis

6. Europe Vaccine Adjuvants Market Analysis - by Adjuvant Class

7. Europe Vaccine Adjuvants Market Analysis - by Type

8. Europe Vaccine Adjuvants Market -Country Analysis

9. Industry Landscape

10. Company Profiles

11. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â